The 89% specificity of serum CEA has been considered too low for use as a single marker for general screening for colon cancer; however, serum CEA recently showed promise for colon cancer screening when used as part of a multianalyte test that combined CEA together with mutation detection from circulating tumor DNA, which showed a 99% specificity.24, 25, 26 This multianalyte panel detected ≈63% of stage I–III CRCs, suggesting an opportunity for additional contribution by markers such as CCSP‐2 that show high sensitivity to early stage CRC. The gene discussed is CEACAM5; the disease is neoplasm.